FDA accepts ceftobiprole's NDA

Key ceftobiprole data published

Basilea research report

Basilea - H1 results and upgrade

Basilea - ceftobiprole filed for US approval

Basilea - Cresemba exceeding expectations

Ceftobiprole delay a minor frustration

Cresemba continues to deliver

Basilea's future in anti-infectives

Another Cresemba Pfizer milestone

Basilea - a year of significant achievement

CHF20m Astellas milestone

Basilea - Cresemba approved in Japan

Basilea - Sustainable profitability

Basilea - Another oncology programme partnered

Basilea - Positive data at IDweek

Basilea - Still capturing value from oncology

Basilea - Focus on anti-infectives apparent

Basilea - Dilution overhang removed

Basilea - H1 results show continued commercial and strategic progress